Charts

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock ("Common Stock") at a price of $2.82 per share and pre-funded warrants to purchase 1,523,404 shares of Common Stock at a price of $2.819 per share of Common Stock issuable upon exercise

Gainers XTL Biopharmaceuticals (NASDAQ:XTLB) shares moved upwards by 13.9% to $2.71 during Wednesday's after-market session. The market ...

Leap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips LPTX stock results show that Leap Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. The post LPTX Stock Earnings: Leap Therapeutics Beats EPS for Q4 2023 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of “America’s Top Trader” Issues A.I. Code Red: Act Now or Miss Out It doesn’t matter if you have $500 or $5 million. Do this now.

Leap Therapeutics (NASDAQ:LPTX) reported its Q4 earnings results on Monday, March 18, 2024 at 07:00 AM. Here's what investors need to ...

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2023.

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced new data from Part A of the DeFianCe study, a Phase 2 study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy in second-line patients with advanced colorectal cancer (CRC), to be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers S

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that enrollment has been completed in the randomized controlled Part C of the DisTinGuish study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, and chemotherapy in patients with advanced gastroesophageal junction and gastric cancer.

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new data in second-line patients with advanced colorectal cancer from the DeFianCe study, a Phase 2 study evaluating DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in combination with standard of care bevacizumab and chemotherapy at the upcoming 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer

Gainers SenesTech (NASDAQ:SNES) stock rose 42.0% to $2.67 during Monday's after-market session. TC BioPharm (Holdings) (NASDAQ:TCBP) ...

Gainers GeneDx Hldgs (NASDAQ:WGS) stock moved upwards by 39.7% to $1.97 during Friday's regular session. The market value of their ...

Shares of FLJ Group Limited (NASDAQ: FLJ) shares jumped during Friday’s session after the company announced it entered into a ...

Gainers Fresh2 Group (NASDAQ:FRES) stock rose 28.4% to $1.22 during Tuesday's regular session. The market value of their outstanding ...

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York, NY.

Raymond James has decided to maintain its Outperform rating of Leap Therapeutics (NASDAQ:LPTX) and lower its price target from $18.50 to ...

Leap Therapeutics (NASDAQ:LPTX) reported its Q3 earnings results on Monday, November 13, 2023 at 07:00 AM. Here's what investors need to ...

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended September 30, 2023.

NEW YORK, NY / ACCESSWIRE / October 24, 2023 / The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic recessions have led to a sharp decline in the sector. Consequently, many small and micro-cap biotech companies are trading at all-time lows, with several down by over 80-90% in recent years. This downturn has led to many biotech firms trading below their cash holdings.

Gainers Better Therapeutics (NASDAQ:BTTX) stock rose 56.7% to $0.49 during Monday's pre-market session. The market value of their ...

In the classic tune by Kenny Rogers, ‘The Gambler,’ he sang, ‘Every hand’s a winner and every hand’s a loser…’ These words hold valuable wisdom that should resonate with every investor. Regardless of your chosen investment strategy, achieving success in the stock market ultimately hinges on mastering the art of balancing risk and reward. Few segments of the stock market offer a higher potential return for the risk involved than the penny stocks, those equities priced at $5 or less. These are sto

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in two upcoming investor conferences:

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors will want to get ready for another busy day of trading as we cover the biggest pre-market stock movers for Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live Wall Street Titan: Here’s My #1 Stock for 2023 The $1 Investment You MUST Take Advantage of Right Now It doesn’t matter if you have $500 or $5 million. Do this now.

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for second quarter ended June 30, 2023.

In this article, we will take a look at the 10 most promising penny stocks according to analysts. To see more such companies, go directly to 5 Most Promising Penny Stocks According to Analysts. Innovation is what drives human societies forward. Major companies of today were once small companies working on innovative and disruptive ideas. […]

Friday's session saw 59 companies set new 52-week lows. Interesting Facts About Today's 52-Week ...

During Thursday, 56 stocks hit new 52-week lows. 52-Week Low Highlights: Bristol-Myers Squibb (NYSE:BMY) was the ...

Wednesday saw 59 companies set new 52-week lows. Key Facts About Today's 52-Week Lows: The largest company by ...

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that, based on the early efficacy and momentum seen in the enrollment of 33 patients with colorectal cancer (CRC) in its DeFianCe study, it has initiated the 130 patient randomized controlled Part B of the Phase 2 study. The study evaluates Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with standard of care bevacizumab and chemotherapy a

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will effect a 10-for-1 reverse stock split of its issued and outstanding common stock, effective at 5PM ET on June 20, 2023. Leap expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on June 21, 2023.

Gainers Recruiter.com Group, Inc. (NASDAQ: RCRT) shares jumped 114% to $0.41. Recruiter.com signed a definitive agreement for ...

In this article we take a look at some of the hot penny stocks that are gaining value. To see more such stocks click 5 Hot Penny Stocks To Buy. Investing in small-cap and micro-cap companies comes with a lot of volatility, surprises and risks. When broader markets are in turmoil, like they are ever […]

Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting new long-term follow-up data in first-line patients with advanced gastric or gastroesophageal junction adenocarcinoma (GEA) from Part A of the DisTinGuish study, a Phase 2 clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with BeiGene's tislelizumab and chemotherapy, at the upcoming 2

Gainers CaliberCos Inc. (NASDAQ: CWD) shares jumped 65.6% to $9.94 amid post-IPO volatility. Enveric Biosciences, Inc. (NASDAQ: ...

Gainers SeaStar Medical Holding Corporation (NASDAQ: ICU) shares surged 101.7% to $1.19 in pre-market trading after dropping ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to start the day with a breakdown of all the biggest pre-market stock movers worth reading about on Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Wall Street Titan: Here’s My #1 Stock for 2023 It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers Sientra (NASDAQ:SIEN) shares increased by 19.1% to $1.93 during Wednesday's pre-market session. The company's market cap stands ...

Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for first quarter ended March 31, 2023.

On Monday, 89 stocks made new 52-week lows. Interesting Facts About Today's 52-Week Lows: Plug Power ...

Leap Therapeutics (NASDAQ:LPTX) has observed the following analyst ratings within the last quarter: Bullish Somewhat ...

Gainers Enzo Biochem (NYSE:ENZ) shares moved upwards by 79.8% to $2.14 during Friday's pre-market session. The market value of their ...

Gainers Enzo Biochem (NYSE:ENZ) stock rose 104.2% to $2.43 during Thursday's after-market session. At the close, Enzo Biochem's trading ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Leap Therapeutics, Inc. (NASDAQ: LPTX) and Flame Biosciences, Inc. is fair to Leap shareholders. Under the terms of the merger agreement, Leap will issue approximately 19,794,373 shares of its common stock and approximately 136,833 shares of a newly designated Series X non-voting convertible preferred stock to Flame stockholders.

Gainers Axcella Health Inc. (NASDAQ: AXLA) rose 71.7% to $0.7450 in pre-market trading after the company reported regulatory path ...

HC Wainwright & Co. has decided to maintain its Buy rating of Leap Therapeutics (NASDAQ:LPTX) and lower its price target from $4.00 ...

Morgan Stanley cut the price target for IBM (NYSE: IBM) from $152 to $148. Morgan Stanley analyst Erik Woodring downgraded the ...

Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided ...

Leap Therapeutics Inc(NASDAQ: LPTX) hasagreed to acquireFlame Biosciences Inc, a privately-held biotechnology ...

Gainers Calyxt (NASDAQ:CLXT) stock increased by 140.3% to $0.45 during Tuesday's pre-market session. The company's market cap stands at ...

Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of ...

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a ...

Gainers Ventyx Biosciences (NASDAQ:VTYX) shares moved upwards by 61.0% to $37.18 during Monday's regular session. ...

Gainers Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating ...

Gainers Performance Shipping Inc. (NASDAQ: PSHG) rose 41.7% to $ 0.94 in pre-market trading. Performance Shipping shares dipped ...

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend ...

Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) shares jumped 325.9% to close at $10.35 on Tuesday after Regeneron ...

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Valneva Says Confident Of ...

Gainers Aptorum Group Limited(NYSE: APM) shares jumped 38.5% to close at $1.69 on Thursday after the company ...